First and later line treatments for familial hypercholesterolemia (FH): Lowering lipids and getting to goal
Cost: FreeView Offer chevron_right
Activity Description / Statement of Need:
In this online, self-learning activity:
Familial hypercholesterolemia (FH), also known as type II hyperlipoproteinemia, is an autosomal dominant genetic disorder characterized by substantially elevated plasma LDL-C levels. There are over 1600 different mutations associated with FH, and the condition arises from a significant or complete reduction in functional LDL-C receptors (LDL-Rs) and an attendant reduction in LDL-C clearance that predisposes individuals to premature atherosclerotic cardiovascular disease (ASCVD). The severity of FH is determined by the presence of heterozygous or homozygous genetic alterations. Patients with homozygous FH develop vascular disease during childhood, while those with heterozygous FH may not develop ASCVD until their 30s or 40s. FH is a relatively common disorder, affecting about 1 in every 299 people in the US. Among people with ischemic heart disease, the prevalence is about 10-fold higher, and among those with severe hypercholesterolemia, the prevalence is nearly 23-fold higher.
This learning activity has been designed to bring HCPs’ knowledge of the strategies for the diagnosis and treatment of FH up to date and to improve their competence and performance in treating it.
Cardiologists, primary care physicians, physician assistants, nurse practitioners, and pharmacists who practice in cardiology; and any other clinicians with an interest in FH.